Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Sumatriptan succinate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
MigraKind is used to treat migraine. These tablets contain sumatriptan, which belongs to a group of medicines called triptans (5-HT, receptor agonists). Migraine symptoms may be caused by the temporary swelling of blood vessels in the head due to a temporary imbalance in the body's natural chemicals. The tablets are believed to work on this imbalance and reduce the swelling of these blood vessels. The tablets help to take away the headache and other symptoms of a migraine attack such as feeling sick (nausea) and sensitivity to light and sound. They start to relieve migraine headache about 30 minutes after you take them.
2.
e MigraKind
Do not take MigraKind:
• • • •
you have diabetes you have high cholesterol you have a close relative who developed early heart disease – either your father or brother developed heart disease before the age of 55, or your mother or sister developed heart disease before the age of 65.
If three or more of the points above apply to you, you may be at higher risk of heart disease- see your doctor without taking If you are a woman who has been through the menopause. In very rare cases, people have developed serious heart conditions after using MigraKind, even though they had no signs of heart disease before. If any of the points above applies to you it could mean you have a greater risk of developing heart disease – so:
3.
MigraKind
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Adults aged 18 to 65
4.
MigraKind can cause side effects, but not everybody gets them. Some symptoms may be caused by the migraine itself. Allergic reactions: get doctor's help straight away The following side effects have occurred but their exact frequency is not known. Some people may be allergic to these tablets. Signs of allergy include rash; hives (itchy rash); wheezing; breathlessness; swollen eyelids, face or lips; complete collapse. If you get any of these symptoms soon after taking MigraKind, don't take any more. Tell a doctor straight away. Take the packaging and this leaflet with you. Very rare side effects: tell doctor as soon as possible (affect less than 1 in 10,000 people)
Liver function changes. If you have a blood test to check your liver function tell your doctor or nurse that you are taking MigraKind.
Common side effects: tell doctor if long or severe (affect less than 1 in 10 people)
Pain, heaviness, pressure or tightness in the chest, throat or other parts of the body, or unusual sensations, including numbness, tingling and warmth or cold. These effects may be intense but generally pass quickly. If these effects continue or become severe (especially the chest pain):
Some patients may get the following side effects but it is not known how often they occur:
5.
MigraKind
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister/carton after 'Exp (MM/YY)'. The expiry date refers to the last day of that month. Do not store above 25 ̊C. Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6.
More about MigraKind
What MigraKind tablet contains
Each film coated tablet contains 50 mg sumatriptan (as the succinate). –
The other ingredients are: Core: lactose monohydrate, lactose, crosscarmellose sodium, microcrystalline cellulose, magnesium stearate. Coating: Lactose monohydrate, mannitol (E421), titanium dioxide (E171), triacetin and talc.
What MigraKind tablet looks like and contents of the pack Round white film coated tablets marked 'RDY' on one face and '292' on the other. Pack sizes: 2, 6 tablets Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer: Dr. Reddy's Laboratories (UK) Ltd, 410 Cambridge Science Park, Milton Road, Cambridge, CB4 0PE, United Kingdom Other formats of this leaflet A service is available to listen to or request a copy of this leaflet in Braille, large print or audio. please contact the marketing authorisation holder at the address above. This leaflet was last revised in August 2025.
MigraKind 50 mg Film-Coated Tablets comes as tablet containing 50mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in MigraKind 50 mg Film-Coated Tablets is sumatriptan succinate.
Medicines with the same active substance, strength and form include: Boots Migraine Relief 50 mg Tablets, Imigran 50mg Tablets, Imigran Radis 50mg Tablets. In total there are 6 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for MigraKind 50 mg Film-Coated Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
MigraKind film-coated tablets are indicated for the acute relief of migraine attacks, with or without aura. MigraKind film-coated tablets should only be used where there is a clear diagnosis of migraine.
Posology
Adults (18-65 years of age)
MigraKind is indicated for the acute intermittent treatment of migraine. It should not be used prophylactically. The recommended dose of Sumibril/Migraitan should not be exceeded.
It is advisable that MigraKind be taken as early as possible after the onset of a migraine attack but it is equally effective at whatever stage of the attack it is administered.
The recommended dose of oral MigraKind is a 50mg tablet. Some patients may require 100mg.
If the patient has responded to the first dose but the symptoms recur, a second dose may be taken provided that there is a minimum interval of 2 hours between the two doses. Not more than two 50 mg tablets (total dose 100mg) may be taken in any 24 hour period or to treat the same attack.
Patients who do not respond to the prescribed dose of MigraKind should not take a second dose for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. MigraKind may be taken for subsequent attacks.
MigraKind is recommended as monotherapy for the acute treatment of migraine and should not be taken concomitantly with ergotamine or derivatives of ergotamine (including methysergide) (see section 4.3).
Paediatric population
The efficacy and safety of sumatriptan (film-coated) tablets/dispersible tablets in children aged less than 10 years have not been established. No clinical data are available in this age group.
The efficacy and safety of sumatriptan (film-coated) tablets/dispersible tablets in children 10 to 17 years of age have not been demonstrated in the clinical trials performed in this age group. Therefore the use of sumatriptan (filmcoated) tablets/dispersible tablets in children 10 to 17 years of age is not recommended (see section 5.1).
Elderly (Over 65 years of age)
Not to be used in those over 65 years of age.
Experience of the use of sumatriptan in patients aged over 65 years is limited.
The pharmacokinetics do not differ significantly from a younger population but until further clinical data are available, the use of MigraKind in patients aged over 65 years is not recommended.
Method of administration
Oral.
The tablets should be swallowed whole with water.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Sumatriptan should not be given to patients who have had myocardial infarction or have ischaemic heart disease, coronary vasospasm (Prinzmetal's angina), peripheral vascular disease or patients who have symptoms or signs consistent with ischaemic heart disease.
• Sumatriptan should not be administered to patients with a history of cerebrovascular accident (stroke) or transient ischaemic attack (TIA).
• Sumatriptan should not be administered to patients with severe hepatic impairment
• The use of sumatriptan in patients with moderate and severe hypertension and mild uncontrolled hypertension is contraindicated
• Concurrent administration of monoamine oxidase inhibitors and sumatriptan is contraindicated.
• MigraKind must not be used within 2 weeks of discontinuation of therapy with MAOIs.
• The concomitant administration of ergotamine or derivatives of ergotamine (including methysergide) or any triptan/5-hydroxytryptamine1 (5-HT1) receptor agonist with sumatriptan is contraindicated (see section 4.5).
MigraKind should only be used where there is a clear diagnosis of migraine.
Sumatriptan is not indicated for use in the management of hemiplegic, basilar or ophthalmoplegic migraine.
Before treating with sumatriptan, care should be taken to exclude potentially serious neurological conditions (e.g. CVA, TIA) if the patient presents with atypical symptoms or if they have not received an appropriate diagnosis for sumatriptan use.
Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness which may be intense and involve the throat (see section 4.8). Where such symptoms are thought to indicate ischaemic heart disease, no further doses of sumatriptan should be given and appropriate evaluation should be carried out.
Sumatriptan should not be given to patients with risk factors for ischaemic heart disease, including those patients who are heavy smokers or users of nicotine substitution therapies, without prior cardiovascular evaluation (see section 4.3).
Special consideration should be given to postmenopausal women and males over 40 with these risk factors. These evaluations however, may not identify every patient who has cardiac disease and, in very rare cases, serious cardiac events have occurred in patients without underlying cardiovascular disease.
Sumatriptan should be administered with caution to patients with mild controlled hypertension, since transient increases in blood pressure and peripheral vascular resistance have been observed in a small proportion of patients (see section 4.3).
There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. Serotonin syndrome has been reported following concomitant treatment with triptans and serotonin noradrenaline reuptake inhibitors (SNRIs).
If concomitant treatment with sumatriptan and an SSRI/SNRI is clinically warranted, appropriate observation of the patient is advised (see section 4.5).
Sumatriptan should be administered with caution to patients with conditions which may affect significantly the absorption, metabolism or excretion of drugs, e.g. impaired hepatic (Child Pugh grade A or B; see section 5.2) or renal function (see sect on 5.2). A 50mg dose should be considered in patients with hepatic impairment.
Sumatriptan should be used with caution in patients with a history of seizures or other risk factors which lower the seizure threshold, as seizures have been reported in association with sumatriptan (see section 4.8).
Patients with known hypersensitivity to sulphonamides may exhibit an allergic reaction following administration of sumatriptan. Reactions may range from cutaneous hypersensitivity to anaphylaxis. Evidence of cross-sensitivity is limited, however, caution should be exercised before using sumatriptan in these patients.
Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John's Wort (Hypericum perforatum).
Prolonged use of any type of painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of Medication Overuse Headache (MOH) should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.
Important information regarding the ingredients in this medicine
MigraKind contains Lactose
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.
Studies in healthy subjects show that sumatriptan does not interact with propranolol, flunarizine, pizotifen or alcohol.
There are limited data on an interaction with preparations containing ergotamine or another triptan/5-HT1 receptor agonist. The increased risk of coronary vasospasm is a theoretical possibility and therefore concomitant administration is contraindicated (see section 4.3)
The period of time that should elapse between the use of sumatriptan and ergotamine-containing preparations or another triptan/5-HT1 receptor agonist is not known. This will also depend on the doses and types of products used. The effects may be additive. It is advised to wait at least 24 hours following the use of ergotamine-containing preparations or another triptan/5-HT1 receptor agonist before administering sumatriptan. Conversely, it is advised to wait at least 6 hours following use of sumatriptan before administering an ergotamine-containing product and at least 24 hours before administering another triptan/5-HT1 receptor agonist.
An interaction may occur between sumatriptan and monoamine oxidase inhibitors (MAOIs) and concomitant administration is contraindicated (see section 4.3).
There have been rare post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of SSRIs and sumatriptan. Serotonin syndrome has also been reported following concomitant treatment with triptans and SNRIs (see section 4.4).
Pregnancy
Post-marketing data from the use of sumatriptan during the first trimester in over 1,000 women are available. Although these data contain insufficient information to draw definitive conclusions, they do not suggest an increased risk of congenital defects. Experience with the use of sumatriptan in the second and third trimester is limited.
Evaluation of experimental animal studies does not indicate direct teratogenic effects or harmful effects on peri- and postnatal development. However, embryo-foetal viability might be affected in the rabbit (see Section 5.3). Administration of sumatriptan should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Breast-feeding
Sumatriptan is excreted into breast milk, with average relative infant doses of < 4% following administration of a single dose of sumatriptan. Infant exposure can be minimised by avoiding breast feeding for 12 hours after treatment during which time any breast milk expressed should be discarded.
There have been reports of breast pain and/or nipple pain following sumatriptan use in breastfeeding women (see section 4.8). The pain was usually transient and disappeared in 3 to 12 hours.
No studies on the effects on the ability to drive and use machines have been performed. Drowsiness may occur as a result of migraine or its treatment with sumatriptan. Caution is recommended when skilled tasks are to be performed e.g. driving or operating machinery
Adverse events are listed below by system organ class and frequency. Frequencies are defined as:
very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available data). Some of the symptoms reported as undesirable effects may be associated symptoms of migraine.
Clinical Trial Data
Nervous System Disorders
Common:
Dizziness, drowsiness, sensory disturbance including paraesthesia and hypoaesthesia.
Vascular Disorders
Common:
Transient increases in blood pressure arising soon after treatment.
Flushing.
Respiratory, Thoracic and Mediastinal Disorders
Common:
Dyspnoea
Gastrointestinal Disorders
Common:
Nausea and vomiting occurred in some patients but it is unclear if this is related to sumatriptan or the underlying condition
Musculoskeletal and Connective Tissue Disorders
Common:
Sensations of heaviness (usually transient and may be intense and can affect any part of the body including the chest and throat).
Myalgia.
General Disorders and Administration Site Conditions
Common:
Pain, sensations of heat or cold, pressure or tightness ( these events are usually transient and may be intense and can affect any part of the body including the chest and throat: Feelings of weakness, fatigue (both events are mostly mild to moderate in intensity and transient).
Investigations
Very rare:
Minor disturbances in liver function tests have occasionally been observed.
Post-Marketing Data
Immune System Disorders
Not known:
Hypersensitivity reactions ranging from cutaneous hypersensitivity to anaphylaxis.
Nervous System Disorders
Not known:
Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent.
Tremor, dystonia, nystagmus, scotoma
Eye Disorders
Not known:
Flickering, diplopia, reduced vision. Loss of vision including reports of permanent defects. However, visual disorders may also occur during a migraine attack itself.
Cardiac Disorders
Not known:
Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, angina, myocardial infarction (see sections 4.3 and 4.4).
Vascular Disorders
Not known:
Hypotension, Raynaud's phenomenon.
Gastrointestinal Disorders
Not known:
Ischaemic colitis, diarrhoea, dysphagia.
Musculoskeletal, Connective Tissue and Bone Disorders
Not known:
Neck stiffness.
Arthralgia.
Psychiatric disorders
Not known:
Anxiety.
Skin and subcutaneous tissue disorders
Not known:
Hyperhidrosis
Reproductive system and breast disorders
Rare:
Breast pain
General Disorders and Administration Site Conditions
Not known:
Pain trauma activated
Pain inflammation activated
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Doses in excess of 400 mg orally were not associated with side effects other than those mentioned in Section 4.8
Treatment
If overdose occurs, the patient should be monitored for at least 10 hours and standard supportive treatment applied as required.
It is unknown what effect haemodialysis or peritoneal dialysis has on the plasma concentrations of Sumatriptan.
Ask anything about MigraKind 50 mg Film-Coated Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.